TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 589919
Drug: 26 g
Normalized name: Sunmark Lancet Thin 26 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26 g of milk chocolate
Study: 30332895
Drug: Memory Work
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memory Work Therapy
Study: 15685825
Drug: Gemcitabine in
Normalized name: gemcitabine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine in combination with paclitaxel
Study: 11723016
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg/d) for 7 days
Study: 11723016
Drug: Pl(A2) carriers
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pl(A2) carriers (no aspirin effect)
Study: 11723016
Drug: Pl(A1A1) subjects
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pl(A1A1) subjects (after aspirin ingestion)
Study: 11723016
Drug: Pl(A2) carriers
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pl(A2) carriers (after aspirin ingestion)
Study: 9220211
Drug: Itraconazole oral
Normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution (200 mg once daily)
Study: 9220211
Drug: Clotrimazole troches
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole troches (10 mg five times daily)
Study: 3552007
Drug: Intermittent positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent positive pressure ventilation (IPPV) with nitrous oxide in oxygen facilitated by atracurium 0.5 mg kg‐1
Study: 27524193
Drug: Four-channel FES
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-channel FES treatment based on normal gait pattern
Study: 27524193
Drug: Single-channel FES
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-channel FES treatment
Study: 20089454
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC) 1.2 g/d for 5 days starting at day 3 of the cycle for 12 consecutive cycles
Study: 10372705
Drug: MK-677 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-677 (25 mg daily for 8 weeks)
Study: 8879912
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for bulimia nervosa
Study: 7048929
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course of ampicillin (three doses)
Study: 22314392
Drug: Amitriptyline (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (exact dosage and duration not specified)
Study: 16919533
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of telmisartan and nisoldipine
Study: 11777359
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral prednisone per day
Study: 2764533
Drug: Oral neomycin-erythromycin
Normalized name: erythromycin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral neomycin-erythromycin
Study: 31564410
Drug: [11C]telmisartan with
Approvals — FDA: no, EMA: no, PMDA: no
Description: [11C]telmisartan with predosing of 80 mg telmisartan (two 40 mg Micardis® tablets)
Study: 31564410
Drug: [11C]telmisartan with
Approvals — FDA: no, EMA: no, PMDA: no
Description: [11C]telmisartan with predosing of 80 mg telmisartan
Study: 23758821
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa or rFSH treatment flexibility options
Study: 23758821
Drug: Receiving rFSH
Normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receiving rFSH on the day of hCG administration
Study: 23758821
Drug: Reduced versus
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced versus fixed-dose of rFSH from day 8
Study: 11359224
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL NS x 1 (n = 10)
Study: 11359224
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL NS x 2 (n = 12)
Study: 7524278
Drug: non-steroidal symptomatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-steroidal symptomatic treatment
Study: 3063290
Drug: Active vitamin
Normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active vitamin D (alphacalcidol), 1 microgram daily
Study: 21235416
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng (KRG) 3 g/day
Study: 18698316
Drug: Betahistine 48
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 48 mg (n=23)
Study: 17070197
Drug: Evaluation while
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation while off any estrogen therapy
Study: 17070197
Drug: Physiologic transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic transdermal E(2) therapy
Study: 12590030
Drug: Once-daily tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tramadol tablets 150 mg
Study: 12590030
Drug: Once-daily tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tramadol tablets 200 mg
Study: 12590030
Drug: Normal release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal release tramadol capsules 50 mg 8-hourly
Study: 1441953
Drug: Continuous irrigation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous irrigation with Ringer solution during cement curing
Study: 3913478
Drug: Mianserin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (30 mg)
Study: 3913478
Drug: Amitryptiline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitryptiline (75 mg)
Study: 19200421
Drug: Lamotrigine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (titrated to 200 mg/d)
Study: 19796716
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate tablets providing elemental calcium at 63 mg/day
Study: 19796716
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate tablets providing elemental calcium at 354 mg/day
Study: 19796716
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate tablets providing elemental calcium at 660 mg/day
Study: 19796716
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate tablets providing elemental calcium at 966 mg/day
Study: 17460023
Drug: Fluconazole prophylaxis
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole prophylaxis (6 mg/kg for 3 weeks, administered orally when enteral feeding achieved)
Study: 8832526
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy including prednisone plus interferon (3 Mu/day induction, 3 Mu three times a week maintenance)
Study: 2076622
Drug: naproxen gel
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen gel (10%)
Study: 2076622
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo gel (base alone)
Study: 6195240
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cephaloridine
Study: 31621150
Drug: Oral tofacitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tofacitinib (TOFA)
Study: 30982549
Drug: Early-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-generation drug-eluting stents (DES)
Study: 21538537
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (extended-release) at doses of 50-300 mg/day
Study: 21538537
Drug: Quetiapine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine IR (immediate-release) at doses of 25-300 mg/day
Study: 19279424
Drug: Topical 0.2
Normalized name: coal tar topical 0.2% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.2 percent glyceryl trinitrate (GTN) ointment
Study: 7547098
Drug: Tenidap sodium
Normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap sodium 120 mg
Study: 2262646
Drug: Salbutamol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.2 mg, four times a day) and inhaled beclomethasone dipropionate (BDP, 0.5 mg, four times a day)
Study: 2262646
Drug: Salbutamol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.2 mg, four times a day)
Study: 29158665
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of MB12066 (10, 30, 100, 150, 200, 300, or 400 mg)
Study: 29158665
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of MB12066 (100 or 200 mg)
Study: 24074269
Drug: 12-month lifestyle
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month lifestyle intervention consisting of weekly group participation for six months on nutrition, physical activity, and lifestyle changes, followed by monthly group participation for an additional six months and individual monthly contacts from facilitators during the second six-month phase.
Study: 10390399
Drug: Chloroquine (CQ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (CQ), 250 mg/d (Maintenance group)
Study: 1991440
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 1200 mg
Study: 1991440
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 600 mg
Study: 29510792
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms (AZT, CPAP, AZT plus CPAP)
Study: 22894725
Drug: Pre-bronchodilator FEV₁
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-bronchodilator FEV₁
Study: 22894725
Drug: Post-bronchodilator FEV₁
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-bronchodilator FEV₁
Study: 17662571
Drug: Lamotrigine (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (200, 300, or 400 mg daily)
Study: 29621901
Drug: Lamotrigine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (up to 400 mg/day)
Study: 10220625
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg TNK-tPA
Study: 10220625
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg TNK-tPA
Study: 10220625
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg TNK-tPA
Study: 10220625
Drug: Overall (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (30 to 50 mg TNK-tPA)
Study: 10220625
Drug: Patients treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated within 6 hours after symptom onset (30 mg TNK-tPA)
Study: 10220625
Drug: Patients treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated within 6 hours after symptom onset (40 mg TNK-tPA)
Study: 25384080
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin (6 mU/min with increments every 45 min)
Study: 25384080
Drug: Intermediate-dose oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermediate-dose oxytocin (3 mU/min with increments every 45 min)
Study: 25384080
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin (6 mU/min with increments every 45 min) in nulliparous women
Study: 25384080
Drug: Intermediate-dose oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermediate-dose oxytocin (3 mU/min with increments every 45 min) in nulliparous women
Study: 25384080
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin (6 mU/min with increments every 45 min) in multiparous women
Study: 25384080
Drug: Intermediate-dose oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermediate-dose oxytocin (3 mU/min with increments every 45 min) in multiparous women
Study: 21884018
Drug: Accelerated infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Accelerated infusion of streptokinase (1.5 MU/20 min)
Study: 21884018
Drug: Conventional infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional infusion of streptokinase (1.5 MU/60 min)
Study: 17310863
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg per day of mirtazapine
Study: 17310863
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg per day of mirtazapine
Study: 15699486
Drug: anti-CD3 monoclonal
Normalized name: Anti-CD3
DrugBank: Muromonab (DB00075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-CD3 monoclonal antibody (hOKT3gamma1(Ala‐Ala))
Study: 9875725
Drug: Ketanserin (serotonin-2A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (serotonin-2A antagonist)
Study: 9875725
Drug: Risperidone (atypical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (atypical antipsychotic)
Study: 9875725
Drug: Haloperidol (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (dopamine antagonist, typical antipsychotic)
Study: 7978432
Drug: IV propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV propofol (1-2 mg/kg) followed by a propofol infusion (75-100 micrograms.kg-1.min-1)
Study: 7978432
Drug: IV thiopental
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV thiopental (1-3 mg/kg) followed by a pentobarbital bolus (2-3 mg/kg)
Study: 2558622
Drug: Cicletanine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine (100 mg/day)
Study: 2558622
Drug: Cicletanine-enalapril combination
Normalized name: cicletanine
DrugBank: Cicletanine (DB12766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine-enalapril combination (100 mg/day cicletanine + 20 mg/day enalapril)
Study: 18642654
Drug: Hypofractionated CyberKnife
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated CyberKnife stereotactic radiosurgery (CKSRS) with a marginal dose of 1800-2000 cGy/3 fractions, 80 to 89% isodose line (mean 83%), mean 97.9% tumor coverage.
Study: 17135615
Drug: High-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exercise group (40 minutes per day of aerobic exercise)
Study: 17135615
Drug: Low-dose exercise
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exercise group (20 minutes per day of aerobic exercise)
Study: 17135615
Drug: High-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exercise group
Study: 12653876
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (anthropometric measures, insulin, HDL- and LDL-cholesterol)
Study: 10732887
Drug: Medical Treatment
Normalized name: Medical air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Treatment
Study: 3903572
Drug: Terbutaline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (1 mg) administered from pressurised aerosol through a nebuhaler
Study: 3903572
Drug: Terbutaline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (4 mg) as nebulised solution
Study: 31442335
Drug: Terbutaline (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (8 x 0.5 mg daily)
Study: 27025829
Drug: Clindamycin 300
Normalized name: clindamycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 300 mg 4 times daily for 7 days
Study: 27025829
Drug: TMP-SMX 320
Normalized name: sulfamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TMP-SMX 320 mg/1600 mg twice daily for 7 days
Study: 24942540
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab (TCZ‐SC) 162 mg every other week
Study: 24942540
Drug: Subcutaneous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous placebo (PBO‐SC) every other week
Study: 22389077
Drug: d‐methamphetamine (0.42
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐methamphetamine (0.42 mg/kg)
Study: 11136839
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 microg/kg per day)
Study: 11136839
Drug: Control (antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (antibiotics ceftazidime and amikacin without G-CSF)
Study: 9847275
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume (VT) below 10 ml/kg of body weight
Study: 9847275
Drug: Conventional ventilatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ventilatory approach with VT at 10 ml/kg or above
Study: 8026282
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus twice daily insulin
Study: 2511683
Drug: Prolonged low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prolonged low-dose intravenous nitroglycerin
Study: 53654
Drug: Single and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple agent chemotherapy
Study: 53654
Drug: No immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immediate treatment
Study: 31150799
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment prescribed after baseline visit
Study: 31150799
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat tolerance test (OFTT) meal ingestion
Study: 30177026
Drug: Artichoke leaf
Normalized name: artichoke leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artichoke leaf extract (ALE) 1800 mg/d (four tablets) for 12 weeks
Study: 23163141
Drug: SQNYPBF (Shenmai
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQNYPBF (Shenmai Injection and Sulfotanshinone Sodium Injection, intravenously dripped once daily for 7 days)
Study: 23163141
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine therapies including anti-infection, nutrition support, and glucose control with insulin pump)
Study: 21209497
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug therapy/rtACS (D/ACS)
Study: 21209497
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group D (conventional drug therapy)
Study: 16675000
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg/day for 2 weeks
Study: 12021952
Drug: Riluzole 50
Normalized name: riluzole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole 50 mg b.i.d.
Study: 6113353
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir (7-day course)
Study: 25012804
Drug: Laparoscopic magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laparoscopic magnetic sphincter augmentation (MSA)
Study: 30031018
Drug: Double-dose proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose proton pump inhibitors (BID PPI)
Study: 28424223
Drug: Low-dose DCB
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose DCB (2-µg/mm2 surface dose of paclitaxel)
Study: 28424223
Drug: Low-dose DCB
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose DCB
Study: 24650952
Drug: Lixisenatide 20
Normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 20 μg once-daily for 24 weeks
Study: 24650952
Drug: Lixisenatide 20
Normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 20 μg once-daily
Study: 19793585
Drug: Cocoa butter
Normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa butter cream
Study: 17686445
Drug: Cisplatin/Gemcitabine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/Gemcitabine therapy
Study: 15848611
Drug: CsA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA treatment with FF genotype
Study: 15848611
Drug: CsA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA and Tac treatment
Study: 15848611
Drug: CsA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA treatment with BB genotype
Study: 9661571
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg vecuronium
Study: 26017787
Drug: Birth preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth preparation program including supervised physical exercise, relaxation exercises, and educational activities